

AxoGen, Inc. to Report First Quarter Financial Results on May 5, 2015

AXGN Investor Conference Call and Webcast Scheduled for Tuesday, May 5, 2015 at 4:30 PM ET

Alachua, FL (PRWEB) April 21, 2015

AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, will report results for the first quarter of 2015 on Tuesday, May 5, 2015 following the close of the market.

The Company will host a conference call and webcast for the investment community following the release at 4:30 PM ET. Investors interested in participating by phone are invited to call toll free at 1.877.407.0993 or use the direct dial-in number 1.201.689.8795. Those interested in joining via the webcast, should visit http://axogeninc.equisolvewebcast.com/q1-2015.

Following the conference call, a replay will be available on the Company's website at www.AxoGenlnc.com, under 'Investors.'

About AxoGen, Inc.

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

Contact:

AxoGen, Inc.

Lee Robert "Bob" Johnston Jr, Chief Financial Officer 386.462.6856 InvestorRelations@AxoGenInc.com

EVC Group

Bob Jones / Michael Polyviou - Investor Relations 646.201.5447/212.850.6020 bjones@evcgroup.com; mpolyviou@evcgroup.com